Actelion provides update on CRTH2 program
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion provides update on CRTH2 program
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 02 April 2012 - Actelion Ltd (SIX: ATLN)
announced today that the company will re-direct its development efforts in the
anti-inflammatory area, focusing on a potent follow-up CRTH2 antagonist
currently in Phase I clinical development.
Two recently concluded studies with the first orally-active CRTH2 antagonist,
setipiprant, in asthma (Phase IIb) and seasonal allergic rhinitis (Phase III
profiling) did not confirm efficacy findings made in earlier studies.
Accordingly, clinical development with this well-tolerated agent in these
indications is being discontinued.
By focusing on the more potent follow-up compound, Actelion expects to further
develop the understanding of the CRTH2 mechanism as a potential anti-
inflammatory mode of action in allergic indications.
###
Notes to the Editor
About setipiprant
Actelion's CRTH2 antagonist, setipiprant, blocks the effects of prostaglandin D2
(PGD2) role in inflammation and, in consequence, the amplification and
maintenance of allergic reactions. It targets the allergic inflammation at the
beginning of the cascade.
Earlier, positive data was obtained with setipiprant in an allergen challenge
proof-of-mechanism study in patients with mild to moderate allergic asthma. In
the 18-patient 2-period crossover double-blind placebo-controlled study, the
compound was well tolerated and demonstrated efficacy versus placebo on the
primary endpoint (FEV1) during the late allergic reaction (3-10 hours) after a
bronchial allergen challenge.
A Phase II study with setipiprant in seasonal allergic rhinitis (SAR) met its
primary endpoint with statistical significance (p<0.05). The two week study
assessed the efficacy and tolerability of various doses of setipiprant in 579
adult patients with SAR ("hay fever") due to mountain cedar pollen. Treatment in
the study was well tolerated across all treatment groups and no serious adverse
events were reported.
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,500 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI®).
For further information please contact:
Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
Press Release PDF:
http://hugin.info/131801/R/1598979/504520.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1598979]
Unternehmensinformation / Kurzprofil:
Datum: 02.04.2012 - 07:00 Uhr
Sprache: Deutsch
News-ID 130698
Anzahl Zeichen: 4586
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion provides update on CRTH2 program"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
